X4 Pharmaceuticals Total Assets Growth & History (XFOR)
X4 Pharmaceuticals's total assets was $290.5M for fiscal 2025.
View full X4 Pharmaceuticals company overviewX4 Pharmaceuticals annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $290.5M | $144.0M | +98.34% |
| 2024 | 2024-12-31 | $146.4M | −$811,000 | −0.55% |
| 2023 | 2023-12-31 | $147.3M | −$8.3M | −5.35% |
| 2022 | 2022-12-31 | $155.6M | $38.4M | +32.78% |
| 2021 | 2021-12-31 | $117.2M | −$5.7M | −4.63% |
| 2020 | 2020-12-31 | $122.9M | −$37.8M | −23.54% |
| 2019 | 2019-12-31 | $160.7M | $150.8M | +1516.03% |
| 2018 | 2018-12-31 | $9.9M | −$71.3M | −87.76% |
| 2017 | 2017-12-31 | $81.3M | — | — |
X4 Pharmaceuticals quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $253.1M | $147.9M | +140.63% |
| Q1 2026 | 2026-03-31 | $270.3M | $140.3M | +107.89% |
| Q4 2025 | 2025-12-31 | $290.5M | $144.0M | +98.34% |
| Q3 2025 | 2025-09-30 | $163.6M | −$14.6M | −8.20% |
| Q2 2025 | 2025-06-30 | $105.2M | −$105.4M | −50.07% |
| Q1 2025 | 2025-03-31 | $130.0M | $17.8M | +15.89% |
| Q4 2024 | 2024-12-31 | $146.4M | −$811,000 | −0.55% |
| Q3 2024 | 2024-09-30 | $178.2M | $4.9M | +2.81% |
| Q2 2024 | 2024-06-30 | $210.6M | $37.2M | +21.46% |
| Q1 2024 | 2024-03-31 | $112.2M | −$12.2M | −9.83% |
| Q4 2023 | 2023-12-31 | $147.3M | −$8.3M | −5.35% |
| Q3 2023 | 2023-09-30 | $173.3M | $59.9M | +52.81% |
| Q2 2023 | 2023-06-30 | $173.4M | $92.4M | +114.02% |
| Q1 2023 | 2023-03-31 | $124.4M | $24.8M | +24.87% |
| Q4 2022 | 2022-12-31 | $155.6M | $38.4M | +32.78% |
| Q3 2022 | 2022-09-30 | $113.4M | −$7.1M | −5.90% |
| Q2 2022 | 2022-06-30 | $81.0M | −$60.6M | −42.81% |
| Q1 2022 | 2022-03-31 | $99.6M | −$61.4M | −38.13% |
| Q4 2021 | 2021-12-31 | $117.2M | −$5.7M | −4.63% |
| Q3 2021 | 2021-09-30 | $120.5M | −$12.6M | −9.47% |
| Q2 2021 | 2021-06-30 | $141.7M | −$875,000 | −0.61% |
| Q1 2021 | 2021-03-31 | $161.0M | $7.3M | +4.76% |
| Q4 2020 | 2020-12-31 | $122.9M | −$37.8M | −23.54% |
| Q3 2020 | 2020-09-30 | $133.1M | $23.6M | +21.54% |
| Q2 2020 | 2020-06-30 | $142.5M | $9.0M | +6.76% |
| Q1 2020 | 2020-03-31 | $153.7M | $91.2M | +145.75% |
| Q4 2019 | 2019-12-31 | $160.7M | $150.8M | +1516.03% |
| Q3 2019 | 2019-09-30 | $109.5M | $63.6M | +138.64% |
| Q2 2019 | 2019-06-30 | $133.5M | $76.3M | +133.36% |
| Q1 2019 | 2019-03-31 | $62.5M | −$6.7M | −9.64% |
| Q4 2018 | 2018-12-31 | $9.9M | −$71.3M | −87.76% |
| Q3 2018 | 2018-09-30 | $45.9M | — | — |
| Q2 2018 | 2018-06-30 | $57.2M | — | — |
| Q1 2018 | 2018-03-31 | $69.2M | — | — |
| Q4 2017 | 2017-12-31 | $81.3M | — | — |
X4 Pharmaceuticals total assets trends
Over the last five fiscal years, X4 Pharmaceuticals's total assets increased from $122.9M to $290.5M, a change of $167.6M. The latest reported quarter, Q2 2026, shows $253.1M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review X4 Pharmaceuticals source filings ↗